Earnings
Home›Earnings›Previews›Definium Therapeutics shares jump on second Phase 3 win
Definium Therapeutics shares jump on second Phase 3 win
Yahoo Finance says Definium Therapeutics disclosed a second positive Phase 3 study for its LSD-based drug, driving the stock higher.
Definium Therapeutics (DFTX) unveiled the second of two positive Phase 3 studies for its LSD-based drug, a development that lifted the biotech stock, Yahoo Finance reports.
The article describes the move as a fresh validation of the company’s late-stage clinical progress, with the shares soaring following the new Phase 3 disclosure.
Yahoo Finance’s piece frames the jump as part of the stock’s reaction to the latest Phase 3 update, noting the drug received a second positive result among the two studies.
← Newer storyKinder Morgan, Phillips 66 and HF Sinclair approve $5 billion Western…Older story →Bessent says US economy outpaces peers, cites growth and investment